Literature DB >> 2524207

Pharmacokinetics of acitretin and its 13-cis metabolite in patients on haemodialysis.

A E Stuck1, C J Brindley, A Busslinger, F J Frey.   

Abstract

1. Plasma concentrations of acitretin and its metabolite (13-cis acitretin) were measured in six patients on haemodialysis and six subjects without renal failure following a single oral dose of 50 mg of acitretin. 2. The mean areas under the plasma concentration vs time curves of acitretin and its metabolite were about 50% lower in patients on haemodialysis. 3. No retinoids were detectable in the dialysate.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2524207      PMCID： PMC1379827          DOI： 10.1111/j.1365-2125.1989.tb05369.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies.

Authors:  J M Geiger; B M Czarnetzki
Journal:  Dermatologica       Date:  1988

2.  Etretinate pharmacokinetics in chronic renal failure. A preliminary study in psoriasis patients.

Authors:  A Vahlquist
Journal:  Dermatologica       Date:  1987

3.  Hemodialysis in the treatment of psoriasis. A controlled trial.

Authors:  A R Nissenson; M Rapaport; A Gordon; R G Narins
Journal:  Ann Intern Med       Date:  1979-08       Impact factor: 25.391

4.  Determination of etretinate and its main metabolite in human plasma using normal-phase high-performance liquid chromatography.

Authors:  U Paravicini; A Busslinger
Journal:  J Chromatogr       Date:  1983-09-09

5.  On metabolism and pharmacokinetics of an aromatic retinoid.

Authors:  U Paravicini; K Stöckel; P J MacNamara; R Hänni; A Busslinger
Journal:  Ann N Y Acad Sci       Date:  1981-02-27       Impact factor: 5.691

6.  Etretinate kinetics during chronic dosing in severe psoriasis.

Authors:  J Massarella; F Vane; C Buggé; L Rodriguez; W J Cunningham; T Franz; W Colburn
Journal:  Clin Pharmacol Ther       Date:  1985-04       Impact factor: 6.875

7.  [Improvement of psoriasis by haemodialysis (author's transl)].

Authors:  I Sprenger-Klasen; H E Franz; O E Rodermund
Journal:  Dtsch Med Wochenschr       Date:  1980-06-27       Impact factor: 0.628

8.  Dialysis treatment and psoriasis in Europe.

Authors:  P Kramer; F P Brunner; H Brynger; C Chantler; R A Donckerwolcke; C Jacobs; N H Selwood; A J Wing
Journal:  Clin Nephrol       Date:  1982-08       Impact factor: 0.975

9.  Single dose pharmacokinetics of etretin and etretinate in psoriatic patients.

Authors:  F G Larsen; P Jakobsen; C G Larsen; A Nørgaard; K Kragballe; F Nielsen-Kudsk
Journal:  Pharmacol Toxicol       Date:  1987-08
  9 in total
  3 in total

Review 1.  Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases.

Authors:  F G Larsen; F Nielsen-Kudsk; P Jakobsen; K Weismann; K Kragballe
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 2.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  Acitretin : A Review of its Pharmacology and Therapeutic Use.

Authors:  Tania Pilkington; Rex N Brogden
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.